Analysts Expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Will Announce Earnings of -$0.32 Per Share

Wall Street analysts expect Aldeyra Therapeutics, Inc (NASDAQ:ALDXGet Rating) to report earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aldeyra Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.36). Aldeyra Therapeutics posted earnings of ($0.28) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 14.3%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Aldeyra Therapeutics will report full-year earnings of ($1.37) per share for the current financial year, with EPS estimates ranging from ($1.76) to ($1.14). For the next year, analysts anticipate that the company will post earnings of ($1.78) per share, with EPS estimates ranging from ($2.20) to ($1.39). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Aldeyra Therapeutics.

Aldeyra Therapeutics (NASDAQ:ALDXGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. During the same quarter in the previous year, the company posted ($0.25) EPS.

A number of research firms recently issued reports on ALDX. Berenberg Bank began coverage on shares of Aldeyra Therapeutics in a report on Tuesday, May 24th. They issued a “buy” rating and a $28.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Aldeyra Therapeutics in a research note on Wednesday, April 27th. Finally, StockNews.com assumed coverage on shares of Aldeyra Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $19.75.

Shares of ALDX traded down $0.15 on Wednesday, reaching $2.94. The company’s stock had a trading volume of 437,959 shares, compared to its average volume of 857,227. The company has a debt-to-equity ratio of 0.08, a current ratio of 13.60 and a quick ratio of 13.60. The stock has a market capitalization of $171.40 million, a P/E ratio of -2.65 and a beta of 1.65. The stock’s 50 day simple moving average is $3.59 and its two-hundred day simple moving average is $4.45. Aldeyra Therapeutics has a 12-month low of $2.36 and a 12-month high of $13.18.

Several institutional investors have recently added to or reduced their stakes in ALDX. Goldman Sachs Group Inc. increased its position in Aldeyra Therapeutics by 1,254.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,391,018 shares of the biotechnology company’s stock worth $6,183,000 after purchasing an additional 1,288,353 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Aldeyra Therapeutics by 3,594.8% during the first quarter. Assenagon Asset Management S.A. now owns 975,139 shares of the biotechnology company’s stock worth $4,334,000 after buying an additional 948,747 shares during the period. UBS Group AG boosted its stake in Aldeyra Therapeutics by 371.2% during the first quarter. UBS Group AG now owns 960,393 shares of the biotechnology company’s stock worth $4,269,000 after buying an additional 756,593 shares during the period. Verition Fund Management LLC boosted its stake in Aldeyra Therapeutics by 54.1% during the first quarter. Verition Fund Management LLC now owns 2,105,907 shares of the biotechnology company’s stock worth $9,361,000 after buying an additional 739,206 shares during the period. Finally, Johnson & Johnson purchased a new position in Aldeyra Therapeutics during the third quarter worth $3,467,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

About Aldeyra Therapeutics (Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

Recommended Stories

Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)

Want More Great Investing Ideas?

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.